Stoke Therapeutics, Inc. Increase (Decrease) in Deferred Liabilities
Stoke Therapeutics, Inc. (STOK) reported Increase (Decrease) in Deferred Liabilities of $28.00 thousand for the 12-month period ending 2019-12-31, per its 10-K filed 2021-03-09.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredLiabilities · last filed 2021-03-09
- Stoke Therapeutics, Inc. increase (decrease) in deferred liabilities for the quarter ending 2019-12-31 was $6.00K.
- Stoke Therapeutics, Inc. increase (decrease) in deferred liabilities for the quarter ending 2019-09-30 was $8.00K.
- Stoke Therapeutics, Inc. increase (decrease) in deferred liabilities for the quarter ending 2019-06-30 was $7.00K.
- Stoke Therapeutics, Inc. increase (decrease) in deferred liabilities for the quarter ending 2019-03-31 was $7.00K.
- Stoke Therapeutics, Inc. increase (decrease) in deferred liabilities for fiscal 2019 was $28.00K.
- Stoke Therapeutics, Inc. increase (decrease) in deferred liabilities for fiscal 2018 was -$10.00K.
| Period end | Increase (Decrease) in Deferred Liabilities 3 month | Increase (Decrease) in Deferred Liabilities 6 month | Increase (Decrease) in Deferred Liabilities 9 month | Increase (Decrease) in Deferred Liabilities 12 month |
|---|---|---|---|---|
| 2019-12-31 | $6.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-09 | $14.00K derived: sum of 2 quarters · filed 2021-03-09 | $21.00K derived: sum of 3 quarters · filed 2021-03-09 | $28.00K 10-K · filed 2021-03-09 |
| 2019-09-30 | $8.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $15.00K derived: sum of 2 quarters · filed 2020-11-12 | $22.00K 10-Q · filed 2020-11-12 | $15.00K derived: sum of 4 quarters · filed 2020-11-12 |
| 2019-06-30 | $7.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $14.00K 10-Q · filed 2020-08-10 | $7.00K derived: sum of 3 quarters · filed 2020-08-10 | $6.00K derived: sum of 4 quarters · filed 2020-08-10 |
| 2019-03-31 | $7.00K 10-Q · filed 2020-05-15 | $0.00 derived: sum of 2 quarters · filed 2020-05-15 | -$1.00K derived: sum of 3 quarters · filed 2020-05-15 | |
| 2018-12-31 | -$7.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-23 | -$8.00K derived: sum of 2 quarters · filed 2020-03-23 | -$10.00K 10-K · filed 2020-03-23 | |
| 2018-09-30 | -$1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | -$3.00K 10-Q · filed 2019-11-12 | ||
| 2018-06-30 | -$2.00K 10-Q · filed 2019-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |